What the studies show
20 weeks of tesamorelin improved some executive-function measures in healthy older adults and those with mild cognitive impairment. Single trial, never replicated or developed further.
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults.Arch Neurol, 2012;69:1420–1429152 adults, 20 weeks; not replicated.
In context
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, approved in the United States to reduce excess abdominal fat in people with HIV-associated lipodystrophy. In that population it cuts visceral fat by about 15% over six months, and the fat returns when treatment stops. Its use for general fat loss, muscle or anti-ageing rests on extrapolation from that specific group; there are no trials in healthy adults. It is not authorised in the EU.
Tesamorelin is approved (rx, us). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Tesamorelin proven to help with cognition in older adults?
What studies are behind the grade?
Is Tesamorelin approved for this?
Other outcomes for Tesamorelin
- AVisceral fat (HIV lipodystrophy)2 phase 3 RCTs (n=816)
- BLiver fat (HIV with NAFLD)1 RCT (n=61)
- DFat loss in healthy adultsNone
- AIGF-1 elevation and glucose effectsadversePhase 3 programme
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →